Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study.
Acetylsalicylic acid
COVID-19
Platelet aggregation inhibitors
SARS-CoV-2
Thrombosis
Journal
International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
received:
04
07
2021
revised:
26
09
2021
accepted:
28
09
2021
pubmed:
8
10
2021
medline:
6
11
2021
entrez:
7
10
2021
Statut:
ppublish
Résumé
Patients with coronavirus disease 2019 (COVID-19) exhibit high thrombotic risk. The evidence on a potential independent prognostic role of antiplatelet treatment in those patients is limited. The aim of the study was to evaluate the prognostic impact of pre-admission low-dose acetylsalicylic acid (ASA) in a wide series of hospitalized patients with COVID-19. This cohort study included 984 COVID-19 patients stratified according to ASA intake before hospitalization: ASA Mean age was 72 [62; 81] with 69% of male patients. ASA In COVID-19 patients undergoing hospitalization, pre-admission treatment with ASA is associated with better in-hospital outcome, mainly driven by less respiratory support upgrade.
Sections du résumé
BACKGROUND
Patients with coronavirus disease 2019 (COVID-19) exhibit high thrombotic risk. The evidence on a potential independent prognostic role of antiplatelet treatment in those patients is limited. The aim of the study was to evaluate the prognostic impact of pre-admission low-dose acetylsalicylic acid (ASA) in a wide series of hospitalized patients with COVID-19.
METHODS
This cohort study included 984 COVID-19 patients stratified according to ASA intake before hospitalization: ASA
RESULTS
Mean age was 72 [62; 81] with 69% of male patients. ASA
CONCLUSIONS
In COVID-19 patients undergoing hospitalization, pre-admission treatment with ASA is associated with better in-hospital outcome, mainly driven by less respiratory support upgrade.
Identifiants
pubmed: 34619262
pii: S0167-5273(21)01499-6
doi: 10.1016/j.ijcard.2021.09.058
pmc: PMC8489263
pii:
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
240-245Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Circulation. 2020 Jul 28;142(4):315-317
pubmed: 32478567
Int J Cardiol. 2021 Feb 1;324:261-266
pubmed: 33002521
Circ Res. 2020 Sep 17;:
pubmed: 32938299
Circ Res. 2020 Jul 31;127(4):571-587
pubmed: 32586214
JAMA. 2020 Aug 25;324(8):799-801
pubmed: 32702090
Drugs. 2020 Sep;80(14):1383-1396
pubmed: 32705604
J Hematol Oncol. 2020 Sep 4;13(1):120
pubmed: 32887634
Lancet Respir Med. 2020 Jul;8(7):681-686
pubmed: 32473124
Crit Care Resusc. 2020 Apr 15;22(2):95-97
pubmed: 32294809
Thromb Haemost. 2020 Nov;120(11):1594-1596
pubmed: 32679595
JACC CardioOncol. 2020 Jun;2(2):350-355
pubmed: 32292919
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910
J Thromb Thrombolysis. 2021 May;51(4):902-904
pubmed: 33826054
J Crit Care. 2019 Apr;50:162-168
pubmed: 30551047
J Am Coll Cardiol. 2020 Jul 7;76(1):122-124
pubmed: 32387623
N Engl J Med. 2021 Aug 26;385(9):790-802
pubmed: 34351721
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Shock. 2017 Jan;47(1):13-21
pubmed: 27984533
Chest. 2012 Feb;141(2 Suppl):e89S-e119S
pubmed: 22315278
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Circulation. 2009 Dec 22;120(25):2577-85
pubmed: 19923168
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Anesth Analg. 2021 Apr 1;132(4):930-941
pubmed: 33093359
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Nat Rev Cardiol. 2021 Mar;18(3):194-209
pubmed: 33214651
Lancet. 2020 May 9;395(10235):1487-1495
pubmed: 32386592
Thromb Res. 2020 Dec;196:359-366
pubmed: 32977137